Target of γ-secretase modulators, presenilin marks the spot
Open Access
- 30 November 2011
- journal article
- comment
- Published by Wiley in The EMBO Journal
- Vol. 30 (23), 4696-4698
- https://doi.org/10.1038/emboj.2011.410
Abstract
GSMs reduce the production of Aβ42 and are promising compounds for the treatment of Alzheimer disease. However, the target and mechanism of GSMs have been controversial. A study published in this issue of The EMBO Journal adds insight into this and shows that GSMs bind directly to the catalytic subunit of γ-secretase leading to altered cleavage of APP.This publication has 11 references indexed in Scilit:
- Novel γ-Secretase Enzyme Modulators Directly Target Presenilin Protein*Online Journal of Public Health Informatics, 2011
- Piperidine Acetic Acid Based γ-Secretase Modulators Directly Bind to Presenilin-1ACS Chemical Neuroscience, 2011
- Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1The EMBO Journal, 2011
- NSAID-Based γ-Secretase Modulators Do Not Bind to the Amyloid-β PolypeptideBiochemistry, 2011
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeuticsNature Reviews Drug Discovery, 2011
- Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric siteNature Communications, 2010
- Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's DiseaseNeuron, 2010
- Substrate-targeting γ-secretase modulatorsNature, 2008
- Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel SiteOnline Journal of Public Health Informatics, 2004
- Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1Nature, 2000